Catalent Pharma Solutions has made two appointments to its Development and Clinical Services division, to further support its global customer needs.
The company has created two new senior leadership roles to support drug development and clinical trial growth in the US, Europe and Asia.
Paul Hegwood, currently VP Operations for the Clinical Supply Services offerings, will assume the new role of VP Operations for the Development and Clinical Services division for the Americas and Asia-Pacific regions.
Meanwhile, Stuart Cryer, currently VP Operations for the Development and Analytical Solutions offerings, will become the new VP Operations for the Development and Clinical Services division for Europe and the Rest of World.
‘These appointments are part of our strategic investment and growth strategy across our global network, especially for our fast-growing Clinical Supply Services network, which comprises eight GMP facilities and over fifty depots across all continents,’ said Scott Houlton, President and CEO, Development and Clinical Services.
‘The move provides further regional customer focus, plus greater local regulatory expertise, and will facilitate faster execution to support our clients’ needs wherever they are in the world.’
Paul Hegwood
Hegwood became VP of Global Operational Excellence for Catalent in April 2011, following an extensive career leading multi-national teams in operations, business development and product engineering.
Prior to this he was VP of Global Operations for Stanadyne Corporation and has held various leadership positions at General Motors and its automotive electronics and technology company, Delphi.
Cryer’s career in the pharmaceutical industry spans more than 25 years. He has worked for a broad range of pharmaceutical organisations including Pfizer, Abbott, GSK and Aptuit. He has held roles in formulation and development, technical support and operational management.
